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A B S T R A C T
Introduction: Treatment of status epilepticus (SE) has not changed in the last few decades,
benzodiazepines plus phenytoin being the most common ﬁrst line treatment. Intravenous levetiracetam
(ivLEV) is a new antiepileptic drug with interesting properties for SE.
Material and methods: Efﬁcacy and effectiveness of ivLEV in SE were assessed in an observational,
multicentric and retrospective study. Efﬁcacywas deﬁned as cessation of seizures in the 24 h subsequent
to starting ivLEV, with no need of any further antiepileptic drug. All patients were treated following the
standard protocol (benzodiazepines plus phenytoin or valproate). ivLEV was used as add-on therapy,
except in those cases with contraindication for the standard protocol, when it was administered earlier.
Results: 40 patients were included, 57% men, with a mean age of 63 years. The most common type of SE
was partial convulsive (90%). ivLEVwas effective in approximately half of the patients (57.5%), in amean
time of 14.4 h. ivLEVwas used as add-on treatment in 26 patients (after benzodiazepines plus phenytoin,
valproate or both) with an efﬁcacy of 46.1%, and as early treatment (pretreatment with benzodiazepines
or nothing) in 14 patients with an efﬁcacy of 78.5% (p 0.048). Adverse events were observed in 15% of
patients.
Conclusions: ivLEV was an effective antiepileptic drug for SE, but its efﬁcacy depends on the timing of its
administration, being more effective when used as early treatment, and less effective as add-on
treatment.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Status epilepticus (SE) is a medical emergency requiring
intensive and prompt treatment in order to improve its
outcome. SE affects 40 patients per 100,000 inhabitants each
year,1 with a mortality of around 20%.1 The International
Classiﬁcation of Epileptic Seizures deﬁnes SE as ‘‘any seizure
lasting for 30 min or longer or intermittent seizures lasting for§ Members of the Spanish Group for the study of intravenous use of levetiracetam
in status epilepticus (GELEVES).
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consciousness’’.2 However, in clinical practice, the term
‘‘impending status epilepticus’’ is used. This term is deﬁned
as any seizure lasting 5 min or longer or intermittent seizures
lasting more than 5 min, situation in which intensive treatment
is mandatory in order to avoid a consolidated SE.
Etiology is the main factor determining the prognosis of SE,3
although the moment in which treatment is started is also
considered crucial. When an SE lasts more than 30 min, neuronal
death can be produced due to the loss of several regulating
mechanisms, and some previously helpful mechanisms may
become harmful, impeding satisfactory resolution of the SE.4
Treatment of SE has not changed in the last few decades.
Currently, benzodiazepines (BZD) (lorazepam or diazepam)
followed by phenytoin (PHT) are still considered as ﬁrst linevier Ltd. All rights reserved.
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70%.8,9 All these guidelines follow the Treiman Veterans Study
conducted in 1998 inwhich no differences were observed between
treatment with lorazepam alone, diazepam plus PHT, or pheno-
barbital alone, whereas PHT alone was less effective.10 Once ﬁrst
line treatment has failed SE is considered refractory. In refractory
generalized tonic-clonic SE aggressive treatment is needed: coma
with anesthetic drugs requiring orotracheal intubation and
mechanical ventilation, usually in an intensive care unit.3–7 The
use of other antiepileptic drugs (AED) prior to the induction of
pharmacological anesthesia should be considered in older patients,
in patients with comorbidities and, specially, in other types of SE.
In partial motor SE and in non convulsive SE previous treatment
with other AED such as valproate (VPA) could be recommended.
Recent studies, comparing the efﬁcacy between VPA and PHT11,12
have not found conclusive differences.
In recent years, some observational studies have shown the
efﬁcacy of levetiracetam (LEV) in treating SE. The ﬁrst studies were
done with oral presentation and including only a few patients,13,14
while more recent series including a large number of patients, and
using intravenous presentation (ivLEV), have also found it to be
effective.15–18 The results of these studies are promising with high
responder rates. But, none of these studies classify patients
according to etiology, SE type or other factors that can greatly
affect the prognosis. To date no comparative study between ivLEV
and VPA or PHT in patients with SE has been published.
In Spain the GELEVE group (Spanish Group for the study of
ivLEV in SE) was set up with its main objective being to determine
the efﬁcacy and safety of ivLEV in patients with SE. A secondary
objective of the group is to compare the efﬁcacy of ivLEV
administered as a ﬁrst or second line treatment (after BZD) with
ivLEV administered as third or fourth line treatment and to look for
factors related to its efﬁcacy such as etiology, loading dose, daily
dose, etc. General accepted guidelines will be followed at all times
and no changes in the usual clinical practice or in the protocols of
each hospital will be accepted.
2. Material and methods
This is a multicentric observational study. We retrospectively
reviewed the medical charts of consecutive patients diagnosed of
SE and treated with ivLEV seen during the year 2008, in eight
Spanish Hospitals: Hospital de Bellvitge, Hospital la Fe in Valencia,
Hospital 12 de Octubre de Madrid, Hospital Josep Trueta in Girona,
Hospital Clı´nico San Carlos de Madrid, Hospital Clı´nico Universi-
tario in Santiago de Compostela, Hospital Universitario Virgen de la
Arrixaca in Murcia and Hospital del Parc Taulı´ in Sabadell.
2.1. Deﬁnitions
SE was diagnosed according to the ILAE deﬁnition: (1) any
seizure lasting for 30 min or longer or (2) intermittent seizures
lasting for longer than 30 min from which the patient did not
regain consciousness. When no motor signs were observed, for
example in patients who suffered a seizure but did not regain
consciousness afterwards, an EEG showing a diagnostic pattern of
SE was needed to conﬁrm the diagnosis.
An SE was classiﬁed according to its semiology into convulsive
SE or non convulsive SE. Convulsive SE included not only
generalized tonic-clonic status epilepticus but also partial complex
or partial simple motor SE such as epilepsia partialis continua. We
also classiﬁed SE according to the level of consciousness and the
EEG into generalized SE, complex partial SE and simple partial SE.
ivLEV was administered in bolus twice a day. We considered
that a loading dose was used if the ﬁrst bolus was equal or superior
to 1000 mg.Efﬁcacy was deﬁned as cessation of seizures in the 24 h after
starting ivLEV, with no need for any further AED. In patients with
convulsive SE, cessation of seizures was considered to have
occurred when the patient was conscious and free of convulsions.
An EEG was performed to assess the end of SE in patients who did
not regain consciousness.
2.2. Inclusion/exclusion criteria
All patients includedwere treated following a standard protocol
(BZD plus PHT or VPA), so ivLEV was used as add-on therapy,
except in those cases with contraindication for the standard
protocol, when ivLEV could be used before. In the standard
protocol the recommended loading doses of diacepam were 5–
10 mg, of clonacepamwere 1–2 mg, of PHT were 18–20 mg/kg and
loading doses of VPA were 20–40 mg/kg. Patients who received
smaller loading doses of PHT or VPA were retreated with an extra
dose before entering in the study.
No generalized tonic-clonic SE were included in our study,
because ivLEVwas administered only in stabilized patientswith no
respiratory or haemodynamic compromise due to the SE. In cases
in whom anesthetic treatment was used prior to ivLEV, we
considered that efﬁcacy of anesthetic treatmentwould be confused
with efﬁcacy of ivLEV, so these patients were excluded.
We considered the following contraindications to this standard
protocol: BZD were contraindicated in respiratory failure and
Lennox–Gastaut syndrome. PHT was contraindicated in hepatic
failure, disorders of heart rhythm and important unpredictable
pharmacological interaction. VPA was contraindicated in hepatic
failure and thrombocytopenia. In summary, ivLEV treatment was
used as ﬁrst, second, third or fourth line treatment.
We classiﬁed patients into two groups, depending on the
treatment received: Early treatment, when ivLEV was adminis-
tered after BZD (or before in case of severe contraindications to
BZD) and Late treatment when ivLEV was administered after BZD
plus PHT or VPA or both.
Anoxic myoclonic SE (because of the implicit poor prognostic)
and patients treated with LEV at home, except if the loading dose
was higher than the daily dose used at home, were excluded. We
also excluded patients when the standard protocol was not
followed for example those who received ivLEV after BZD without
contraindications for PHT or VPA.
2.3. Variables
The following demographic variables were recorded: gender,
age, concomitant illness, concomitant treatment and previous
history of epilepsy. Other variables recorded were: semiology,
etiology, previous AED used, ivLEV loading doses, daily LEV doses,
efﬁcacy of ivLEV, adverse events, SE resolution with other drugs
and mortality.
We classiﬁed patients according to etiology into several groups.
Acute symptomatic (which includes acute stroke, inﬂammatory
diseases of the CNS, cranial trauma, and meningoencephalitis),
remote symptomatic, tumoral, toxic-metabolic, due to changes/
stop/noncompliance of antiepileptic treatment, genetic and
indeterminate.
2.4. Statistics
Statistical analysis was performed using SPSS 12.0 forWindows
(SPSS Inc., Chicago, IL, USA). Univariate analysis was performed. In
the univariate analysis categorical variables were analyzed using a
one-tailed chi-square analysis (with Yates correction when
warranted) and continuous data were analyzed using t-tests and
ANOVA tests.
Table 1
Demographic and clinical characteristics.
Number range %
Number of patients 40
Men 23 57.5
Age 63.5 (19–92)
Previous history of epilepsy 13 32.5
Comorbidity 29 74.4
Symptomatology
Convulsive 36 90
Non-convulsive 4 10
Status type
Generalized 3 7.5
Simple partial 9 22.5
Complex partial 28 70
Table 3
Treatment and prognosis.
Total range %
Pretreatment (before ivLEV)
Nothing 5 12.5
BZD 8 20
VPA 1 2.5
BZD+PHT 11 27.5
BZD+VPA 11 27.5
BZD+PHT+VPA 4 10
LEV treatment
Early ivLEV 14 35
Late ivLEV 26 65
Treatment LEV at home 2 5
Loading ivLEV dose 29 72.5
Dose loading ivLEV dose (mg) 1275 (1000–1500)
Dose ivLEV daily (mg/d) 1948 (1000–4000)
SE resolution with ivLEV 23 57.5
Time to resolution (h) 14.4 (0.1–24)
SE resolution 36 90
Mortality 1 month 7 17.5
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Fifty-two patients diagnosed of SE and treated with ivLEV were
collected. Forty were included and 12 were excluded (two with an
anoxic-myoclonic SE, two patients who had previously received
LEV at home, seven because the standard protocol was not
followed and one because efﬁcacy of ivLEV could not be assessed
because of immediate hemodialysis).
See Table 1 for general demographic characteristics: 23 of the
patients (57.5%) were men, the mean age was 63.5 years (range
19–92), 32.5% had previously been diagnosed of epilepsy, 2 of them
treated with LEV. According to the semiology of SE, 90% were
partial convulsive and 10% non convulsive. Most of the patients
suffered complex partial SE (70%), only 22.5% were simple partial
SE and 7.5% were primary generalized. In the group of primary
generalized SE one patient suffered a tonic SE while the other two
suffered an absence SE. The most frequent etiology (see Table 2)
was acute symptomatic (25%) with acute stroke being the most
frequent subgroup (7 patients), followed by the toxic-metabolic
etiology in seven patients (5 with an hepatic encephalopathy),
tumoral in six patients, change/stop/noncompliance of the
treatment in ﬁve patients, remote symptomatic in ﬁve and genetic
in two. In addition to the AED, acute illnesses were intensively
treated when it was possible. Comorbidity (dementia, cerebrovas-
cular pathology, tumors, infectious diseases, severe cardiopathy
and severe hepatopathy) was present in 75% of patients.Table 2
Etiology of SE.
Number %
Acute symptomatic 10 25
Ischaemic stroke 4
Haemorragic stroke 3
Cavernoma 1
Cranial-trauma 1
Infectious 1
Remote symptomatic 5 12.5
Tumoral 6 15
Benign 1
Malign 5
Toxic-metabolic 7 17.5
Drugs 1
Hepatic encephalopathy 5
Electrolytic 1
Change/Stop/not compliance AED 5 12.5
Genetic 2 5
Unknown 5 12.5In order to conﬁrm SE cessation an EEG was performed in 9
patients, continuous video-EEGmonitoring in 5 patients, mainly to
control anesthetic coma. ivLEV was found to be efﬁcacious in
approximately half of the patients (23, 57.5%), in a mean time of
14.4 h (range 10 min to 24 h). See Table 3. A loading dose was
administered in 72.5% of the patients, with amean dose of 1275 mg
(range 1000–1500 mg) and the mean daily dose was 1948 mg/day
(range 1000–4000 mg/day). ivLEV was administered as Early
treatment in 14 patients with an efﬁcacy of 78.5% (in 5 ivLEV
was administeredwithout previous BZD, in three because of severe
hepatic encephalopathy, in one patient due to a diagnosis of
Lennox–Gastaut syndrome and in one due to a previous severe
respiratory disease). In 26 patients ivLEV was administered as Late
treatment or add-on treatment with an efﬁcacy of 46.1% (in 11
patients the treatment administered was BZD + PHT + LEV, in 11 it
was BZD + VPA + LEV and in 4 it was BZD + PHT + VPA + LEV). The
efﬁcacy rates observed in these three subgroupswere: 54.5%, 36.3%
and 50% respectively. Differences in efﬁcacy between Early and
Late treatment groups were statistically signiﬁcant (p 0.048). See
Fig. 1a and b.
Looking at efﬁcacy in terms of etiology, less efﬁcacy were
observed in the tumoral (33.3%) and acute symptomatic (50%)
groups, while higher efﬁcacy was found for the change/stop/
noncompliance of AED group (60%) and the toxic-metabolic group
(57.1%); ﬁnally, the highest efﬁcacy was observed in the remote
symptomatic and the indeterminate groups (both 80%). These
differences were not statistically signiﬁcant.
We reviewed the efﬁcacy of ivLEV in relation to the status type,
and found no signiﬁcant differences. We also looked at the efﬁcacy
of ivLEV in relation to the daily doses of ivLEV and whether a
loading dose of ivLEV was administered or not, but no signiﬁcant
difference was found.
Adverse events were observed in 15% of the patients, the most
frequently reported adverse event being somnolence (in 5 of the 6
patients who suffered adverse events). Somnolence was mainly
referred by patients with simple partial SE. The other patient
presented agitation that required ivLEV to be discontinued. In one
case of SEwith a toxic-metabolic etiology, excluded from the study
due to lack of information about efﬁcacy, a severe thrombocyto-
penia was observed, requiring ivLEV to be discontinued.
Finally, SE was resolved in 90% of cases (regardless of whether
ivLEV was the last drug or the patient needed more drugs), and 7
patients died (17.5%) during the following month due to the acute
illness (tumoral progression, infection, etc.) or due to complica-
tions related to the SE.
[()TD$FIG]
Fig. 1. Efﬁcacy of ivLEV in relation (a) to its use as early/late treatment and (b) the
moment of administration. BZD: benzodiazepines; VPA: valproate; PHT: phenytoin;
LEV: levetiracetam; SE: status epilepticus.
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LEV is a new generation drug approved in Europe for use in
partial epilepsy as monotherapy in adults and children over 16
years old and also in generalized epilepsies as an add-on therapy.19
LEV is a well tolerated, broad spectrum, highly effective drug. Also,
it is not protein bound,20 is mainly eliminated by the kidney, and
has no relevant drug interactions.21 All these characteristics make
LEV an interesting drug for treatment of SE, although it has no
indication yet.
In summary, the main ﬁnding of this study was that ivLEV is
effective in the treatment of SE. In approximately half of the
included patients ivLEV was effective, and the factors related to
efﬁcacy are the number of AED previously employed. When ivLEV
is used as Early treatment (ﬁrst or second line) the results aremuch
better, with an efﬁcacy of 78%, in contrast, used as Late treatment
(third or fourth line) it has an efﬁcacy of 46%. The reason for this is
simple: it is more difﬁcult to treat a refractory SE. See Fig. 1a and b.
Some previously published studies have observed efﬁcacy rates
of 70% or more. The excellent results found by Knake et al.15 of a
94% efﬁcacy rate in 16 patients may be due to the fact that in these
patients ivLEV was used only in BZD resistant SE, so there were no
refractory SE patients. Similar ﬁndings (78%), and for the same
reason, can be observed in the study of Berning et al.16 that
included 32 patients in whom the majority (27) were treated with
ivLEV just after BZD. In other studies where ivLEV was used as a
second or third line agent, such as that of Ru¨egg et al.17 with 50
critically ill patients, half of them SE, lower efﬁcacy rates were
found, around 67%. The study conducted by Mo¨ddel et al.18 on 36
patients, in most of whom ivLEV was used as a third line agent
(after BZD or other AED), achieved an efﬁcacy rate of 69%.
In our study the etiology also seems to be an important variable,
although our results are not statistically signiﬁcant. Patients with
the symptomatic remote etiology, the change/stop/noncompliancegroup and the toxico-metabolic group responded better to ivLEV
(80%, 60% and 57%), the worst response rates were for the acute
symptomatic (50%) and tumoral (33%) groups, the indeterminate
group achieving the best results (80%). In the study by Mo¨ddel
et al.18 the group with no lesions on neuroimaging had a better
outcome, this result being statistically signiﬁcant. Otherwise, their
results were similar to ours and suggest that etiology is a key
variable in determining whether ivLEV is successful or not.
In our study ivLEV was well tolerated with only 15% of patients
suffering adverse events. All the studies conductedwith ivLEV have
been consistent in reporting few side effects, mostly not serious. In
our study ivLEV was discontinued in only one patient who
presented agitation. The incidence of agitation or infections has
been observed more frequently in patients than in controls in
clinical trials.22 Themost frequent side effect observed in our study
was somnolence. Sedation has been also documented by other
authors.15 In addition, slight transient thrombocytopenia was
observed in two patients without hematological disorders.17 Other
side effects reported previously are: nausea, vomiting and altered
hepatic function.16,18
In our study no deaths could be attributed to the administration
of ivLEV. There were four deaths within the observation time in
other studies, representing 6% of each study population.15,17
However, all of these deaths could be attributed to the underlying
disease, rather than to the use of ivLEV.
The main limitations of our study were its retrospective nature,
lack of homogeneous drug doses between different centers and the
small number of patients. Although we have found differences in
efﬁcacy comparing treatment groups, comparisons between
etiology groups do not reach statistical signiﬁcance due to sample
size limitations.
In conclusion, after reviewing all the published papers and our
own results, ivLEV seems to be an effective drug for the treatment
of SE. It could be used in cases of contraindication of ﬁrst line
treatments. Although we made an effort to adhere to the standard
protocol we have observed a considerable proportion of patients
(35%) who suffered an SE and had formal contraindications for the
use of PHT, VPA and in some cases also BZD. This group of patients
(older with comorbidities and polypharmacy) will always be
excluded in comparative studies assessing efﬁcacy of ivLEV versus
PHT or VPA and hence ivLEVmay be considered specially indicated
for these patients. Also, like add-on therapy, ivLEV used after VPA
or PHT, while somewhat less effective, is still an option to consider
before the induction of anesthetic coma, in cases of elderly patients
or nonconvulsive SE.
Nevertheless, all the published studies are retrospective and
involve a relatively small number of patients, so their conclusions
must be taken with caution. It is necessary to elaborate
prospective, randomized and comparative trials in order to verify
these results. Furthermore, clinical trials are needed to compare
efﬁcacy of early LEV with early VPA or early PHT.
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